Exploring a new treatment for retinal diseases using a specific agonist
Investigation of a first-in-class Frizzled4/LRP5 agonist in retinal disease models
This study is exploring a new treatment that could help protect and heal the retina, which is important for good vision, and it might lead to better options for people with eye conditions like diabetic retinopathy and macular degeneration.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Minnesota NIH-funded |
| Lab location | 1 site (Minneapolis, United States) |
| Project ID | NIH-11006269 on NIH RePORTER |
What this research studies
This research investigates a novel agonist that targets the Frizzled4 and LRP5 receptors to restore function to the blood-retina barrier, which is crucial for retinal health. By using various mouse models that mimic different retinal diseases, the study aims to understand how this agonist can activate signaling pathways that protect and repair the retina. Patients may benefit from insights gained about potential new therapies for conditions like diabetic retinopathy and macular degeneration.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals suffering from retinal diseases such as diabetic retinopathy, uveitis, or other conditions affecting the blood-retina barrier.
Not a fit: Patients with retinal diseases not related to blood-retina barrier dysfunction may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that improve vision and quality of life for patients with retinal diseases.
How similar studies have performed: While the approach of using a Frizzled4/LRP5 agonist is novel, similar strategies targeting blood-brain and blood-retina barriers have shown promise in preliminary studies.
Where this research is happening
Minneapolis, United States
- University of Minnesota — Minneapolis, United States (Active)
Researchers
- Principal investigator: Junge, Harald — University of Minnesota
- Study coordinator: Junge, Harald
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.